This edition of the Genetic Technology TOE depicts trends across targeted therapies. Few important targeted therapy innovations have been presented along with summary of clinical trials for CAR T 19 and CTL019 therapies.
The focus of the TOE is on disease screening and management. The corresponding clinical trials scenario is also depicted along with the industry interactions. In particular, clinical trial analysis and industry interactions around CRISPR/Cas-9 gene editing are highlighted.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Innovations Across the Targeted Therapy Landscape
- First-in-class CAR-T-Cell Therapy Garners US FDA Approval
- Actemra (Tocilizumab) Receives US FDA Approval for CAR T-cell-induced Cytokine Release Syndrome (CRS)
- Antibody Therapeutics for the Management of Fibrosis
- Dimension Therapeutics to be Acquired by REGENXBIO
Clinical Trial Analysis and Industry Interactions
- Summary of Clinical Trials for CAR T 19 and CTL019 Therapies
- Summary of Key Contacts